SCHEMBL5773167

SCHEMBL5773167

COc1ccc(N2Cc3cnc(Cl)nc3N(C(C)CO[Si](c3ccccc3)(c3ccccc3)C(C)(C)C)C2=O)c(F)c1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR4 P22455 8/20 0.33
EGFR P00533 11/20 0.33
CSF1R P07333 10/20 0.33
TUBB4A P04350 1/20 0.33
TUBB P07437 1/20 0.33
PDGFRB P09619 1/20 0.33
TUBA3C P0DPH7 1/20 0.33
KDR P35968 1/20 0.33
TUBA1B P68363 1/20 0.33
TUBA4A P68366 1/20 0.33
TUBB4B P68371 1/20 0.33
TUBB3 Q13509 1/20 0.33
TUBB2A Q13885 1/20 0.33
TUBB8 Q3ZCM7 1/20 0.33
TUBA3E Q6PEY2 1/20 0.33
TUBA1A Q71U36 1/20 0.33
TUBA1C Q9BQE3 1/20 0.33
TUBB6 Q9BUF5 1/20 0.33
TUBB2B Q9BVA1 1/20 0.33
TUBB1 Q9H4B7 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5773162 1.00 FGFR4 (0.33) FGFR4EGFRCSF1RTUBB4ATUBB
SCHEMBL5830617 0.88 FGFR4 (0.39) FGFR4EGFRPDGFRBKDRFGFR1
SCHEMBL5772097 0.88 FGFR4 (0.39) FGFR4EGFRPDGFRBKDRFGFR1
SCHEMBL5772092 0.88 FGFR4 (0.39) FGFR4EGFRPDGFRBKDRFGFR1
SCHEMBL5830960 0.88 FGFR4 (0.46) FGFR4EGFRCSF1RPDGFRBKDR
SCHEMBL5830726 0.87 FGFR4 (0.45) FGFR4EGFRCSF1RPDGFRBKDR
SCHEMBL5831041 0.79 EGFR (0.40) FGFR4EGFRCSF1RPDGFRBKDR
SCHEMBL5831038 0.79 EGFR (0.40) FGFR4EGFRCSF1RPDGFRBKDR
SCHEMBL5830612 0.77 FGFR4 (0.53) FGFR4EGFRCSF1RPDGFRBKDR
SCHEMBL5831572 0.77 FGFR4 (0.54) FGFR4EGFRCSF1RPDGFRBKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7115740-B2 Pyrimido compounds having antiproliferative activity HOFFMANN-LA ROCHE INC. (US) 2006-10-03 US claimed
US-20040204427-A1 Pyrimido compounds having antiproliferative activity CHEN YI (US) 2004-10-14 US claimed
US-7115740-B2 Pyrimido compounds having antiproliferative activity HOFFMANN-LA ROCHE INC. (US) 2006-10-03 US disclosed
EP-1615928-A1 PYRIMIDO COMPOUNDS F.HOFFMANN-LA ROCHE AG (CH) 2006-01-18 EP disclosed
WO-2004089955-A1 PYRIMIDO COMPOUNDS F.HOFFMANN-LA ROCHE AG (CH) 2004-10-21 WO disclosed
US-20040204427-A1 Pyrimido compounds having antiproliferative activity CHEN YI (US) 2004-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040204427-A1 Pyrimido compounds having antiproliferative activity FGFR3, FGFR1, FGFR4 FGFR4 3/4885EGFR 41/4885CSF1R 480/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.